AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25219389
Drug: Algorithm-based pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm-based pharmacological treatment
Trial: 18274692
Drug: Guideline dissemination,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline dissemination, educational session, plus individualised treatment advice
Trial: 11360070
Drug: Ketoconazole 400
RxNorm normalized name: ketoconazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 400 mg daily for 7 days (treated partners)
Trial: 8083713
Drug: Etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide phosphate at 150 mg/m2/d
Trial: 8083713
Drug: Etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide phosphate (various doses: 50, 75, 100, 125, 150, 175, and 200 mg/m2/d)
Trial: 2587982
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aerosol spray
Trial: 1234503
Drug: Chlordiazepoxide hydrochloride
RxNorm normalized name: Chlordiazepoxide Hydrochloride
DrugBank: Chlordiazepoxide (DB00475)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide hydrochloride (20 mg)
Trial: 31422111
Drug: CA125-guided diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA125-guided diuretic treatment
Trial: 25933495
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal (HF; 46 g fat, 1210 kcal)
Trial: 25933495
Drug: Low-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat meal (LF; 15 g fat, 1214 kcal)
Trial: 24468780
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg of eravacycline/kg intravenously every 12 h for a total of seven doses over 4 days
Trial: 17489325
Drug: Triptorelin (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (monthly injection, group 1; n = 40)
Trial: 15278236
Drug: Operative or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative or conservative therapies in sentinel node-positive patients
Trial: 11309436
Drug: Optimized-treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized-treatment arm (40 mg mitomycin C with pharmacokinetic manipulations and urine alkalinization)
Trial: 11309436
Drug: Standard-treatment arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-treatment arm (20 mg mitomycin C without pharmacokinetic manipulations or urine alkalinization)
Trial: 2023746
Drug: Aminocaproic acid
RxNorm normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminocaproic acid (Amicar) 50 mg/kg every 4 hours for 5 days (max 30 g daily)
Trial: 2023746
Drug: Prednisone 40
RxNorm normalized name: prednisone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 40 mg daily (adjusted for weight) in two divided doses
Trial: 6452796
Drug: Nomifensine (large
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensine (large doses)
Trial: 6452796
Drug: Zimelidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine (75 mg)
Trial: 6452796
Drug: Zimelidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine (150 mg)
Trial: 28848225
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide supplementation (up to a maximum of 3 times 450 mg daily)
Trial: 11133624
Drug: 0.078 microg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.078 microg/mL sufentanil
Trial: 11133624
Drug: 0.156 microg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.156 microg/mL sufentanil
Trial: 11133624
Drug: 0.312 microg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.312 microg/mL sufentanil
Trial: 11133624
Drug: 0.468 microg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.468 microg/mL sufentanil
Trial: 8021737
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide (VP-16) at 50 mg/m2
Trial: 8021737
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide (VP-16) at 60 mg/m2
Trial: 8021737
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide (VP-16) at 75 mg/m2
Trial: 2915763
Drug: L-carnitine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine therapy (1 g i.v.) at the end of dialysis for 1 month, followed by L-carnitine added to the dialysate (2 g in group 1, 4 g in group 2) for 3 months
Trial: 2915763
Drug: L-carnitine added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine added to the dialysate (2 g in group 1, 4 g in group 2)
Trial: 2915763
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of L-carnitine (2 g)
Trial: 28526046
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon angioplasty with or without bail-out bare metal stenting
Trial: 28526046
Drug: Primary stenting
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary stenting with drug-eluting stents
Trial: 25623382
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser treatment (L group)
Trial: 23010700
Drug: 10% sucralfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sucralfate ointment
Trial: 21169874
Drug: Lacto‐Wolfberry (LWB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacto‐Wolfberry (LWB) 13.7 g/d for 90 days
Trial: 9177507
Drug: Acid infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acid infusion (0.1 N HCl at 6-8 cc/min)
Trial: 9177507
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (0.9 N saline)
Trial: 2859047
Drug: Ro31-1118 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro31-1118 (10 mg orally)
Trial: 2859047
Drug: Ro31-1118 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro31-1118 (20 mg orally and intravenously)
Trial: 2859047
Drug: Ro31-1118 (40,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro31-1118 (40, 80, 160, and 320 mg orally)
Trial: 2859047
Drug: Ro31-1118 (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro31-1118 (320 mg)
Trial: 2859047
Drug: Ro31-1118 (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro31-1118 (not specified dose)
Trial: 26956551
Drug: Testosterone pretreatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone pretreatment (10 mg transdermal gel for 21 days)
Trial: 23152846
Drug: Ginger preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger preparation
Trial: 20186829
Drug: High-dose ghrelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ghrelin (13 microg/kg daily)
Trial: 20186829
Drug: Low-dose ghrelin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ghrelin (0.7 microg/kg daily)
Trial: 17595201
Drug: Oral Amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Amoxicillin
Trial: 16327738
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of the EORTC QLQ-SAT32 questionnaire
Trial: 16327738
Drug: Interview administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interview administration of the EORTC QLQ-SAT32 questionnaire
Trial: 11926620
Drug: Grapeseed extract
RxNorm normalized name: Radiance Grapeseed Extract 100mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapeseed extract (GSE) 100 mg, twice daily
Trial: 7653811
Drug: Acetaminophen with
RxNorm normalized name: acetaminophen with codeine ORAL ELIXIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen with codeine (1 mg/kg)
Trial: 28719078
Drug: Luseogliflozin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luseogliflozin (2.5 mg, newly administered)
Trial: 28719078
Drug: Metformin (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1500 mg, newly or additionally administrated)
Trial: 24908387
Drug: Voluntary transition
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voluntary transition to oral methadone
Trial: 23652909
Drug: Isotretinoin 20
RxNorm normalized name: isotretinoin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 20 mg orally once daily for 3 months
Trial: 23652909
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (glucose capsules) for 3 months after isotretinoin therapy
Trial: 18428023
Drug: Acute insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute insulin response (AIR)
Trial: 16132058
Drug: 250 ml/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml/day of Sicilian red wine for 4 weeks
Trial: 10838463
Drug: Hypocaloric diet
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric diet + resistance exercise + casein protein (1.5 g/kg/day)
Trial: 23834666
Drug: BAX326 (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAX326 (recombinant factor IX); Dosage: 49.5 (±4.8) IU kg(‐1) per infusion, administered twice weekly for a mean duration of 6.2 (±0.7) months
Trial: 23834666
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control group (on-demand treatment)
Trial: 20070299
Drug: 1-year maintenance
RxNorm normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1-year maintenance after a 6-week cycle of early intravesical chemotherapy (epirubicin, 80 mg/50 mL)
Trial: 20070299
Drug: Maintenance regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance regimen with monthly instillations for 1 year
Trial: 17445330
Drug: Outreach intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Outreach intervention for providers and CBD agents
Trial: 17445330
Drug: Provider-based activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider-based activities with concurrent demand creation activities
Trial: 16199428
Drug: Ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl estradiol 35 mg/cyproterone acetate 2 mg (EE/CPA: 21/28 days cycle)
Trial: 16199428
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of rosiglitazone and EE/CPA
Trial: 12955342
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy for mild incontinence
Trial: 12955342
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy for moderate incontinence
Trial: 9537132
Drug: Topical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical mitomycin C (0.2 mg/ml, 0.02%)
Trial: 8182273
Drug: Formalin‐inactivated, alum‐adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formalin‐inactivated, alum‐adjuvanted hepatitis A vaccine (VAQTA)
Trial: 3802604
Drug: Sublingual isosorbide
RxNorm normalized name: isosorbide dinitrate Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual isosorbide dinitrate (ISDN) 5 mg
Trial: 28468077
Drug: Jitai tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jitai tablet
Trial: 28468077
Drug: Jitai tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jitai tablet plus buprenorphine
Trial: 23774044
Drug: Myofascial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial treatment in the masseter and temporalis muscles
Trial: 19808138
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of levofloxacin 500 mg
Trial: 17034283
Drug: Yunzhi-Danshen capsules
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yunzhi-Danshen capsules (3.6 g Yunzhi and 1.4 g Dangshem daily for 16 weeks)
Trial: 17034283
Drug: Placebo (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12 capsules daily for 16 weeks)
Trial: 17034283
Drug: Yunzhi-Danshen capsules
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yunzhi-Danshen capsules
Trial: 15073259
Drug: 0.01 mg
RxNorm normalized name: urea 0.01 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mg rhTSH
Trial: 15073259
Drug: 0.03 mg
RxNorm normalized name: biotin 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg rhTSH
Trial: 2945811
Drug: Teicoplanin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (0.2 g)
Trial: 2945811
Drug: Vancomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (1 g)
Trial: 28805281
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg and Caffeine 100 mg
Trial: 24837773
Drug: First dose
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose of MMR at 8 months
Trial: 24837773
Drug: First dose
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose of MMR at 12 months
Trial: 24837773
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups after first dose of MMR
Trial: 24837773
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups after second dose of MMR
Trial: 22257994
Drug: Chlorhexidine-based skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine-based skin preparation solution
Trial: 22257994
Drug: Iodine-based skin
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine-based skin preparation solution
Trial: 20483888
Drug: Electronic metronome
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic metronome without therapy but limited support (5-10 minutes instruction and on-demand telephone assistance) for four weeks (early group)
Trial: 20483888
Drug: Electronic metronome
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic metronome without therapy but limited support (5-10 minutes instruction and on-demand telephone assistance) for four weeks (late group)
Trial: 11792137
Drug: tirofiban +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tirofiban + heparin
Trial: 10367823
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (1600 microg/d for 21 days)
Trial: 7739681
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (group 3)
Trial: 2199866
Drug: Cefazolin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (2 g intravenously)
Trial: 2199866
Drug: Cefotetan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (2 g intravenously)
Trial: 7028047
Drug: Ciclopiroxolamine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclopiroxolamine cream
Trial: 26325026
Drug: CogniPlus method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CogniPlus method with dynamic balance training (20 cognitive training sessions twice per week for 10 weeks)
Trial: 15033676
Drug: Non-5-FU chemotherapy
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Non-5-FU chemotherapy (cis/carboplatin, anthracycline, cyclophosphamide)
Trial: 15033676
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil (5-FU) with glyceroltrinitrate pre-treatment
Trial: 15033676
Drug: Non-5-FU chemotherapy
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Non-5-FU chemotherapy
Trial: 7749824
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (2.4 g daily)
Trial: 7749824
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil with vitamin E (2.4 g daily)
Trial: 2261209
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Idarubicin
Trial: 2261209
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Idarubicin under non-fasting conditions
Trial: 31068015
Drug: Adjunctive chronotype-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive chronotype-based bright light therapy (30 minutes a day for 3 weeks, illuminance: 4246 lux, irradiance: 1802.81 µW.cm‐2)
Trial: 31068015
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with multimodal psychiatric treatment
Trial: 18832520
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily (OD) 3 g mesalazine granules
Trial: 18832520
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times daily (TID) 1 g mesalazine granules
Trial: 14739800
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen administration adjusted to arterial oxygen tensions of approximately 150 mmHg
Trial: 14739800
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen administration adjusted to arterial oxygen tensions of approximately 300 mmHg
Trial: 15848976
Drug: Sugar-free chewing
RxNorm normalized name: Equate Nicotine Polacrilex 2mg Sugar-Free Chewing Gum (Fruit)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-free chewing gum in addition to oral health education (Group G)
Trial: 15848976
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education (Group E)
Trial: 1959195
Drug: Nisoldipine 5
RxNorm normalized name: nisoldipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 5 mg and 10 mg twice daily
Trial: 1959195
Drug: Nisoldipine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 2.5 mg, 5 mg, 10 mg twice daily
Trial: 1959195
Drug: Nisoldipine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 2.5 mg and 5 mg twice daily
Trial: 30383184
Drug: Durvalumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (20 mg/kg every 4 weeks) + tremelimumab (1 mg/kg every 4 weeks for 4 cycles, followed by durvalumab (10 mg/kg every 2 weeks))
Trial: 30383184
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg/kg every 2 weeks) monotherapy
Trial: 30383184
Drug: Tremelimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (10 mg/kg every 4 weeks for 7 doses then every 12 weeks for 2 doses) monotherapy
Trial: 8062939
Drug: Cetrorelix 5
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix 5 mg (group 1)
Trial: 8062939
Drug: Cetrorelix 3
RxNorm normalized name: cetrorelix 3 mg subcutaneous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix 3 mg (group 2)
Trial: 29648859
Drug: Alliance focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alliance focused therapy
Trial: 27062069
Drug: Group psychotherapy
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group psychotherapy + lodenafil 80 mg/one tablet per week (Group 4)
Trial: 27062069
Drug: Lodenafil 80
RxNorm normalized name: Lodenafil carbonate
DrugBank: Lodenafil carbonate (DB11927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lodenafil 80 mg/one tablet per week (Group 3)
Trial: 20568384
Drug: Montelukast, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast, 5 mg